{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:28:09Z","timestamp":1789972089918,"version":"4.0.1"},"reference-count":90,"publisher":"FapUNIFESP (SciELO)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Bras Endocrinol Metab"],"published-print":{"date-parts":[[2006,8]]},"abstract":"<jats:p>Osteoporosis is the result of bone loss due to an imbalance in bone turnover such that bone resorption exceeds bone formation. Bisphosphonates are potent inhibitors of osteoclast activity that reduce bone turnover and re-establish the balance between bone resorption and formation. In clinical studies, several bisphosphonates prevent bone loss, preserve bone structure, improve bone strength and, in patients with osteoporosis, substantially reduce fracture risk. They are effective in multiple clinical settings including postmenopausal osteoporosis, low bone mass in men and drug-induced bone loss. Intermittent oral dosing and intravenous administration are more convenient than the original daily dosing regimen. These drugs are generally well tolerated and have an excellent safety profile in that serious side effects are uncommon. Potent bisphosphonates are generally the preferred treatment option for most patients with or at risk for osteoporosis.<\/jats:p>","DOI":"10.1590\/s0004-27302006000400018","type":"journal-article","created":{"date-parts":[[2006,12,12]],"date-time":"2006-12-12T17:30:21Z","timestamp":1165944621000},"page":"735-744","source":"Crossref","is-referenced-by-count":19,"title":["Bisphosphonates"],"prefix":"10.1590","volume":"50","author":[{"given":"Michael","family":"McClung","sequence":"first","affiliation":[{"name":"Oregon Osteoporosis Center,  USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis and treatment","volume":"285","year":"2001","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMra053077","article-title":"Bone quality: the material and structural basis of bone strength and fragility","volume":"354","author":"Seeman E","year":"2006","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/jbmr.5650111021","article-title":"Markers of bone resorption predict hip fractures in elderly women: The EPIDOS prospective study","volume":"11","author":"Garnero P","year":"1996","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01623652","article-title":"Rationale for the use of alendronate in osteoporosis","volume":"5","author":"Kanis JA","year":"1995","journal-title":"Osteoporos Int","ISSN":"https:\/\/id.crossref.org\/issn\/0937-941X","issn-type":"print"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11914-003-0008-5","article-title":"Mechanism of action of bisphosphonates","volume":"1","author":"Reszka AA","year":"2003","journal-title":"Curr Osteoporos Rep"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1359\/JBMR.041114","article-title":"Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling","volume":"20","author":"Riggs BL","year":"2005","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","article-title":"Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling","volume":"99","author":"Chesnut CH","year":"1995","journal-title":"Am J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9343","issn-type":"print"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1185\/030079904125003566","article-title":"Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis","volume":"20","author":"Harris ST","year":"2004","journal-title":"Curr Med Res Opin","ISSN":"https:\/\/id.crossref.org\/issn\/0300-7995","issn-type":"print"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","article-title":"Monthly oral ibandronate therapy in postmenopausal osteoporosis: one year results from the MOBILE study","volume":"20","author":"Miller PD","year":"2005","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis","volume":"282","author":"Harris ST","year":"1999","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone HG","year":"2004","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis","volume":"19","author":"Chesnut III CH","year":"2004","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/jbmr.5650091003","article-title":"The bone-remodeling transient: Implications for the interpretation of clinical studies of bone mass changes","volume":"9","author":"Heaney RP","year":"1994","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S8756-3282(00)00376-8","article-title":"Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women","volume":"27","author":"Boivin GY","year":"2000","journal-title":"Bone","ISSN":"https:\/\/id.crossref.org\/issn\/8756-3282","issn-type":"print"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bone.2006.01.161","article-title":"Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: Sequential triple biopsy studies with micro-computed tomography","volume":"39","author":"Borah B","year":"2006","journal-title":"Bone","ISSN":"https:\/\/id.crossref.org\/issn\/8756-3282","issn-type":"print"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","article-title":"Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis","volume":"100","author":"Chavassieux PM","year":"1997","journal-title":"J Clin Invest","ISSN":"https:\/\/id.crossref.org\/issn\/0021-9738","issn-type":"print"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"333","author":"Liberman UA","year":"1995","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black DM","year":"1996","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial","volume":"280","author":"Cummings SR","year":"1998","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis","volume":"11","author":"Reginster J","year":"2000","journal-title":"Osteoporos Int","ISSN":"https:\/\/id.crossref.org\/issn\/0937-941X","issn-type":"print"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung MR","year":"2001","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial","volume":"85","author":"Black DM","year":"2000","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1185\/030079903125003125","article-title":"Efficacy of risedronate on clinical vertebral fractures within six months","volume":"20","author":"Roux C","year":"2004","journal-title":"Curr Med Res Opin","ISSN":"https:\/\/id.crossref.org\/issn\/0300-7995","issn-type":"print"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00223-003-0042-4","article-title":"Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis","volume":"74","author":"Harrington JT","year":"2004","journal-title":"Calcif Tissue Int","ISSN":"https:\/\/id.crossref.org\/issn\/0171-967X","issn-type":"print"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","article-title":"Seven years of treatment with risedronate in women with postmenopausal osteoporosis","volume":"75","author":"Mellstrom DD","year":"2004","journal-title":"Calcif Tissue Int","ISSN":"https:\/\/id.crossref.org\/issn\/0171-967X","issn-type":"print"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jcem.85.1.6267","article-title":"Antifracture efficacy of antiresorptive agents are related to changes in bone density","volume":"85","author":"Wasnich RD","year":"2000","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","article-title":"Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs","volume":"112","author":"Cummings SR","year":"2002","journal-title":"Am J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9343","issn-type":"print"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/JCD:7:3:255","article-title":"Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk","volume":"7","author":"Watts NB","year":"2004","journal-title":"J Clin Densitom"},{"issue":"6","key":"ref29","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell R","year":"2003","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1359\/JBMR.051018","article-title":"Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial","volume":"21","author":"Bauer DC","year":"2006","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref31","first-page":"253","article-title":"The use of alendronate for prevention of postmenopausal osteoporosis","volume":"128","author":"McClung M","year":"1998","journal-title":"Ann Intern Med","ISSN":"https:\/\/id.crossref.org\/issn\/0003-4819","issn-type":"print"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1359\/JBMR.040326","article-title":"Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension","volume":"19","author":"Ensrud KE","year":"2004","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03339822","article-title":"Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis","volume":"12","author":"Schnitzer T","year":"2000","journal-title":"Aging Clin Exp Res"},{"key":"ref34","first-page":"711","article-title":"Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis","volume":"101","author":"Luckey MM","year":"2003","journal-title":"Obstet Gynecol","ISSN":"https:\/\/id.crossref.org\/issn\/0029-7844","issn-type":"print"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study","volume":"9","author":"Pols HA","year":"1999","journal-title":"Osteoporos Int","ISSN":"https:\/\/id.crossref.org\/issn\/0937-941X","issn-type":"print"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1210\/jc.2003-031672","article-title":"Prevention of postmenopausal bone loss: six-year results from the early postmenopausal intervention cohort","volume":"89","author":"McClung MR","year":"2004","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archinte.163.7.789","article-title":"Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial","volume":"163","author":"Ascott-Evans BH","year":"2003","journal-title":"Arch Intern Med","ISSN":"https:\/\/id.crossref.org\/issn\/0003-9926","issn-type":"print"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll E","year":"2000","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref39","first-page":"396","article-title":"Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up","volume":"83","author":"Mortensen L","year":"1998","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00296-005-0004-4","article-title":"Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study","volume":"26","author":"Ringe JD","year":"2006","journal-title":"Rheumatol Int","ISSN":"https:\/\/id.crossref.org\/issn\/0172-8172","issn-type":"print"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1359\/jbmr.0301202","article-title":"Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis","volume":"19","author":"McClung MR","year":"2004","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","article-title":"Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study","volume":"54","author":"Delmas PD","year":"2006","journal-title":"Arthritis Rheum","ISSN":"https:\/\/id.crossref.org\/issn\/0004-3591","issn-type":"print"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1359\/JBMR.040920","article-title":"Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study","volume":"20","author":"Rosen CJ","year":"2005","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1385\/JCD:5:2:143","article-title":"Efficacy and tolerability of cyclical intravenous pamidronate in patients with low bone mass","volume":"5","author":"Younes H","year":"2002","journal-title":"J Clin Densitom"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid IR","year":"2002","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2165\/00002512-200623040-00002","article-title":"Long-term safety of bisphosphonate therapy for osteoporosis: a review of the evidence","volume":"23","author":"Liberman UA","year":"2006","journal-title":"Drugs Aging","ISSN":"https:\/\/id.crossref.org\/issn\/1170-229X","issn-type":"print"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1001\/archinte.160.4.517","article-title":"Upper gastrointestinal tract safety profile of alendronate: the Fracture Intervention Trial","volume":"160","author":"Bauer DC","year":"2000","journal-title":"Arch Intern Med","ISSN":"https:\/\/id.crossref.org\/issn\/0003-9926","issn-type":"print"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00198-002-1370-3","article-title":"Tolerability and compliance with risedronate in clinical practice","volume":"14","author":"Hamilton B","year":"2003","journal-title":"Osteoporos Int","ISSN":"https:\/\/id.crossref.org\/issn\/0937-941X","issn-type":"print"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.maturitas.2006.01.011","article-title":"Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety","volume":"54","author":"Epstein S","year":"2006","journal-title":"Maturitas","ISSN":"https:\/\/id.crossref.org\/issn\/0378-5122","issn-type":"print"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/pmj.76.897.417","article-title":"Hypoparathyroidism unmasked by alendronate","volume":"76","author":"Kashyap AS","year":"2000","journal-title":"Postgrad Med J","ISSN":"https:\/\/id.crossref.org\/issn\/0032-5473","issn-type":"print"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4158\/EP.12.1.48","article-title":"Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature","volume":"12","author":"Maalouf NM","year":"2006","journal-title":"Endocr Pract"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s002230010036","article-title":"Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage","volume":"69","author":"Li J","year":"2001","journal-title":"Calcif Tissue Int","ISSN":"https:\/\/id.crossref.org\/issn\/0171-967X","issn-type":"print"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina CV","year":"2005","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00198-003-1571-4","article-title":"Alendronate in the prevention of osteoporosis: 7-year follow-up","volume":"15","author":"Sambrook PN","year":"2004","journal-title":"Osteoporos Int."},{"key":"ref55","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Systematic review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo SB","year":"2006","journal-title":"Ann Intern Med","ISSN":"https:\/\/id.crossref.org\/issn\/0003-4819","issn-type":"print"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1600-0714.2006.00391.x","article-title":"Osteonecrosis of the jaws in patients treated with bisphosphonates: histomorphologic analysis in comparison with infected osteoradionecrosis","volume":"35","author":"Hansen T","year":"2006","journal-title":"J Oral Pathol Med","ISSN":"https:\/\/id.crossref.org\/issn\/0904-2512","issn-type":"print"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1259\/dmfr\/27458726","article-title":"Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws","volume":"35","author":"Chiandussi S","year":"2006","journal-title":"Dentomaxillofac Radiol","ISSN":"https:\/\/id.crossref.org\/issn\/0250-832X","issn-type":"print"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.14219\/jada.archive.2005.0108","article-title":"Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper","volume":"136","author":"Migliorati CA","year":"2005","journal-title":"J Am Dent Assoc","ISSN":"https:\/\/id.crossref.org\/issn\/0002-8177","issn-type":"print"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/rheumatology\/keh481","article-title":"Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip: A prospective open-label study","volume":"44","author":"Agarwala S","year":"2005","journal-title":"Rheumatology","ISSN":"https:\/\/id.crossref.org\/issn\/0080-2727","issn-type":"print"},{"key":"ref60","first-page":"2155","article-title":"The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis: A randomized clinical study","volume":"87","author":"Lai KA","year":"2005","journal-title":"J Bone Joint Surg Am","ISSN":"https:\/\/id.crossref.org\/issn\/0021-9355","issn-type":"print"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1902\/jop.2005.76.7.1113","article-title":"Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study","volume":"76","author":"Lane N","year":"2005","journal-title":"J Periodontol","ISSN":"https:\/\/id.crossref.org\/issn\/0022-3492","issn-type":"print"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1902\/jop.2004.75.12.1579","article-title":"Effect of alendronate on periodontal disease in postmenopausal women: a randomized placebo-controlled trial","volume":"75","author":"Rocha ML","year":"2004","journal-title":"J Periodontol","ISSN":"https:\/\/id.crossref.org\/issn\/0022-3492","issn-type":"print"},{"key":"ref63","first-page":"349","article-title":"Safety of oral bisphosphonates: controlled studies on alveolar bone","volume":"21","author":"Jeffcoat MK","year":"2006","journal-title":"Int J Oral Maxillofac Implants","ISSN":"https:\/\/id.crossref.org\/issn\/0882-2786","issn-type":"print"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/BF02556671","article-title":"The acute phase response after bisphosphonate administration","volume":"41","author":"Adami S","year":"1987","journal-title":"Calcif Tissue Int","ISSN":"https:\/\/id.crossref.org\/issn\/0171-967X","issn-type":"print"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1016\/S0272-6386(03)00214-2","article-title":"Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity","volume":"41","author":"Banerjee D","year":"2003","journal-title":"Am J Kidney Dis","ISSN":"https:\/\/id.crossref.org\/issn\/0272-6386","issn-type":"print"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","article-title":"Toxic acute tubular necrosis following treatment with zoledronate (Zometa)","volume":"64","author":"Markowitz GS","year":"2003","journal-title":"Kidney Int."},{"key":"ref67","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","article-title":"Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial","volume":"44","author":"Adachi JD","year":"2001","journal-title":"Arthritis Rheum","ISSN":"https:\/\/id.crossref.org\/issn\/0004-3591","issn-type":"print"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s002230001146","article-title":"Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy","volume":"67","author":"Wallach S","year":"2000","journal-title":"Calcif Tissue Int","ISSN":"https:\/\/id.crossref.org\/issn\/0171-967X","issn-type":"print"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00198-003-1426-z","article-title":"Osteoporosis after solid organ and bone marrow transplantation","volume":"14","author":"Cohen A","year":"2003","journal-title":"Osteoporos Int","ISSN":"https:\/\/id.crossref.org\/issn\/0937-941X","issn-type":"print"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1097\/01.ASN.0000087092.53894.80","article-title":"Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate","volume":"14","author":"Coco M","year":"2003","journal-title":"J Am Soc Nephrol","ISSN":"https:\/\/id.crossref.org\/issn\/1046-6673","issn-type":"print"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1210\/jc.2004-1444","article-title":"Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial","volume":"90","author":"Fuleihan Gel-H","year":"2005","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"issue":"2","key":"ref72","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.3816\/CBC.2005.s.006","article-title":"Strategies to prevent chemotherapy-induced bone loss in women with breast cancer","volume":"5","author":"Theriault RL","year":"2005","journal-title":"Clin Breast Cancer"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith MR","year":"2001","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith MR","year":"2003","journal-title":"J Urol","ISSN":"https:\/\/id.crossref.org\/issn\/0022-5347","issn-type":"print"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.pcan.4500846","article-title":"Bone mineral density changes on androgen deprivation therapy for prostate cancer and response to antiresorptive therapy","volume":"9","author":"Yaturu S","year":"2006","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref76","first-page":"1687","article-title":"Low-dose intravenous pamidronate reduces fractures in childhood osteoporosis","author":"Gandrud LM","year":"2003","journal-title":"J Pediatr Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0334-018X","issn-type":"print"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1210\/jc.2005-2036","article-title":"Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy","volume":"91","author":"Rauch F","year":"2006","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jbspin.2004.09.005","article-title":"Effect of alendronate therapy in children with osteogenesis imperfecta","volume":"72","author":"Vyskocil V","year":"2005","journal-title":"Joint Bone Spine"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1440-1754.2005.00718.x","article-title":"Proposals for prevention and management of steroid-induced osteoporosis in children and adolescents","volume":"41","author":"Brown JJ","year":"2005","journal-title":"J Paediatr Child Health","ISSN":"https:\/\/id.crossref.org\/issn\/1034-4810","issn-type":"print"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1007\/s00198-005-1972-7","article-title":"A prospective study of changes in bone turnover and bone density associated with regaining weight in women with anorexia nervosa","volume":"16","author":"Bolton JG","year":"2005","journal-title":"Osteoporos Int."},{"key":"ref81","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1210\/jc.2004-2042","article-title":"Low bone formation in premenopausal women with idiopathic osteoporosis","volume":"90","author":"Donovan MA","year":"2005","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1210\/jc.2003-031885","article-title":"Effects of risedronate on bone density in anorexia nervosa","volume":"89","author":"Miller KK","year":"2004","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1210\/jc.2004-1659","article-title":"Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial","volume":"90","author":"Golden NH","year":"2005","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1701-2163(16)30461-3","article-title":"Management of low bone mineral density in premenopausal women","volume":"27","author":"Khan A","year":"2005","journal-title":"J Obstet Gynaecol Can"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/01.GME.0000123641.76105.B5","article-title":"Changes in bone density and turnover after alendronate or estrogen withdrawal","volume":"1","author":"Wasnich RD","year":"2004","journal-title":"Menopause","ISSN":"https:\/\/id.crossref.org\/issn\/1072-3714","issn-type":"print"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"875","DOI":"10.7326\/0003-4819-137-11-200212030-00008","article-title":"Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis: A randomized, double-blind, placebo-controlled trial","volume":"137","author":"Greenspan SL","year":"2002","journal-title":"Ann Intern Med."},{"key":"ref87","first-page":"720","article-title":"Alendronate and estrogen effects in postmenopausal women with low bone mineral density","volume":"85","author":"Bone HG","year":"2000","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref88","first-page":"1890","article-title":"Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women","volume":"86","author":"Harris ST","year":"2001","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1001\/jama.289.19.2525","article-title":"Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial","volume":"289","author":"Greenspan SL","year":"2003","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s11914-996-0018-1","article-title":"Combination therapy for osteoporosis: considerations and controversy","volume":"3","author":"Binkley N","year":"2005","journal-title":"Curr Osteoporos Rep"}],"container-title":["Arquivos Brasileiros de Endocrinologia &amp; Metabologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abem\/v50n4\/31874.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T16:41:04Z","timestamp":1495730464000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-27302006000400018&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":90,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S0004-27302006000400018"],"URL":"https:\/\/doi.org\/10.1590\/s0004-27302006000400018","relation":{},"ISSN":["0004-2730"],"issn-type":[{"value":"0004-2730","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}